
1. antimicrob agents chemother. 2019 oct 22;63(11). pii: e00802-19. doi:
10.1128/aac.00802-19. print 2019 nov.

plasmodium falciparum kelch propeller polymorphisms clinical isolates from
ghana 2007 2016.

matrevi sa(1), opoku-agyeman p(1), quashie nb(1)(2), bruku s(1), abuaku b(1),
koram ka(1), fox a(3), letizia a(3), duah-quashie no(4).

author information: 
(1)department epidemiology, noguchi memorial institute medical research,
college health sciences, university ghana, legon, ghana.
(2)centre tropical clinical pharmacology therapeutics, school medicine
and dentistry, college health sciences, university ghana, legon, ghana.
(3)united states naval medical research unit 3, ghana laboratory, accra, ghana.
(4)department epidemiology, noguchi memorial institute medical research,
college health sciences, university ghana, legon, ghana
nduah@noguchi.ug.edu.gh.

the continuous surveillance polymorphisms kelch propeller domain of
plasmodium falciparum africa important discovery actual
markers artemisinin resistance region. information markers
is crucial control strategies involving chemotherapy chemoprophylaxis for
residents nonimmune travelers country. polymorphisms kelch
propeller domain ghanaian malaria parasites three different ecological
zones several time periods assessed. total 854 archived samples
(2007 2016) collected uncomplicated malaria patients aged ≤9 years old
from 10 sentinel sites used. eighty-four percent wild-type sequences
(pf3d7_1343700), many mutants mostly nonsynonymous mutations
clustered around codons 404 650. variants different amino acid changes of
the codons associated artemisinin (art) resistance validated markers were
observed ghanaian isolates: frequencies i543i, i543s, i543v, r561p, r561r,
and c580v 0.12% 0.6% r539i. mutations reported african
parasites, a578s (0.23%) q613l (0.23%), also observed. three persisting 
nonsynonymous (ns) mutations, n599y (0.005%), k607e (0.004%), v637g (0.004%),
were observed 3 5 time periods nationally. presence variants 
the validated markers artemisinin resistance well persisting
polymorphisms 14 years artemisinin-based combination therapy use argues 
for continuous surveillance markers. molecular markers artemisinin 
resistance observed variants monitored subsequently part of
ongoing surveillance antimalarial drug efficacy/resistance studies the
country.

doi: 10.1128/aac.00802-19 
pmcid: pmc6811449
pmid: 31427297  [indexed medline]

